Limits...
Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer.

Glasgow M, Vogel RI, Burgart J, Argenta P, Dusenbery K, Geller MA - Gynecol Oncol Res Pract (2016)

Bottom Line: The Kaplan-Meier estimate and 95 % CI for PFS at 5 years was 66 % (48-78 %).Fifteen patients (37 %) had medical record documentation of lymphedema following treatment.After additional follow-up, OS and PFS estimates remain high and in-field recurrences low following "sandwich" therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN USA.

ABSTRACT

Background: Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometrial cancer and to assess the lymphedema rates associated with this therapy.

Methods: Women with advanced-stage or recurrent endometrial cancer were recruited between 9/2004 and 6/2009 to our previously published Phase II trial. Patients received intravenous docetaxel (75 mg/m2) and carboplatin (AUC = 6) every 3 weeks for 3 cycles before and after radiation therapy. Patient outcomes were updated in July 2014. Data abstracted included presence of lymphedema, disease progression, and death. OS and PFS estimates at 5 years were calculated using Kaplan-Meier methods.

Results: Of the 41 patients enrolled, 10 (24 %) had stage IIIA and 21 (51 %) had stage IIIC disease; 32 (78 %) had endometrioid histology; and 35 (85 %) completed the protocol. With a median follow-up of 5 years, 15 of 41 patients have died. The Kaplan-Meier estimate and 95 % CI for OS at 5 years was 70 % (53-82 %). Excluding the two patients with recurrent disease at enrollment, 15 of 39 patients progressed or died during follow-up. The Kaplan-Meier estimate and 95 % CI for PFS at 5 years was 66 % (48-78 %). Fifteen patients (37 %) had medical record documentation of lymphedema following treatment.

Conclusions: After additional follow-up, OS and PFS estimates remain high and in-field recurrences low following "sandwich" therapy. The "sandwich" method remains efficacious for women with stage III-IV or recurrent endometrial cancer.

No MeSH data available.


Related in: MedlinePlus

Overall survival for study participants
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4940984&req=5

Fig1: Overall survival for study participants

Mentions: Updated data resulted in patients being followed for a median of 5 years (range: 0.5–9.6 years). One patient was lost to follow-up after treatment completion due to moving out of the country. There have been eight additional deaths since the initial report. Of the 41 patients enrolled, 15 patients died since the start of treatment (Fig. 1). The Kaplan–Meier estimate and 95 % CI for OS at 3 years was 75 % (59–86 %) and 5 years was 70 % (53–82 %); estimated median OS was 8.2 years.Fig. 1


Long term follow-up of a phase II trial of multimodal therapy given in a "sandwich" method for stage III, IV, and recurrent endometrial cancer.

Glasgow M, Vogel RI, Burgart J, Argenta P, Dusenbery K, Geller MA - Gynecol Oncol Res Pract (2016)

Overall survival for study participants
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4940984&req=5

Fig1: Overall survival for study participants
Mentions: Updated data resulted in patients being followed for a median of 5 years (range: 0.5–9.6 years). One patient was lost to follow-up after treatment completion due to moving out of the country. There have been eight additional deaths since the initial report. Of the 41 patients enrolled, 15 patients died since the start of treatment (Fig. 1). The Kaplan–Meier estimate and 95 % CI for OS at 3 years was 75 % (59–86 %) and 5 years was 70 % (53–82 %); estimated median OS was 8.2 years.Fig. 1

Bottom Line: The Kaplan-Meier estimate and 95 % CI for PFS at 5 years was 66 % (48-78 %).Fifteen patients (37 %) had medical record documentation of lymphedema following treatment.After additional follow-up, OS and PFS estimates remain high and in-field recurrences low following "sandwich" therapy.

View Article: PubMed Central - PubMed

Affiliation: Department of Obstetrics, Gynecology and Women's Health, Division of Gynecologic Oncology, University of Minnesota, Minneapolis, MN USA.

ABSTRACT

Background: Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometrial cancer and to assess the lymphedema rates associated with this therapy.

Methods: Women with advanced-stage or recurrent endometrial cancer were recruited between 9/2004 and 6/2009 to our previously published Phase II trial. Patients received intravenous docetaxel (75 mg/m2) and carboplatin (AUC = 6) every 3 weeks for 3 cycles before and after radiation therapy. Patient outcomes were updated in July 2014. Data abstracted included presence of lymphedema, disease progression, and death. OS and PFS estimates at 5 years were calculated using Kaplan-Meier methods.

Results: Of the 41 patients enrolled, 10 (24 %) had stage IIIA and 21 (51 %) had stage IIIC disease; 32 (78 %) had endometrioid histology; and 35 (85 %) completed the protocol. With a median follow-up of 5 years, 15 of 41 patients have died. The Kaplan-Meier estimate and 95 % CI for OS at 5 years was 70 % (53-82 %). Excluding the two patients with recurrent disease at enrollment, 15 of 39 patients progressed or died during follow-up. The Kaplan-Meier estimate and 95 % CI for PFS at 5 years was 66 % (48-78 %). Fifteen patients (37 %) had medical record documentation of lymphedema following treatment.

Conclusions: After additional follow-up, OS and PFS estimates remain high and in-field recurrences low following "sandwich" therapy. The "sandwich" method remains efficacious for women with stage III-IV or recurrent endometrial cancer.

No MeSH data available.


Related in: MedlinePlus